Malignant melanoma, poses a significant health concern globally as it has a high mortality. Although it’s the most serious form of skin cancer, it is curable if diagnosed ahead of time. So, an early and accurate diagnosis plays a crucial role in improving patient outcomes. BioGenex, a leading biotechnology company, offers an exceptional product Anti-MART-1 (Melan-A) mouse monoclonal antibody for the diagnosis of melanoma. This article explores the significance of this antibody, its role in diagnosing melanoma, how it aids in identifying potential precursors and also in management of this deadly disease.
Understanding Melanoma and its Precursor, Melanoma in Situ:
Malignant melanoma is a neoplasm of melanocytes mostly in the skin, but may also occur in the eyes, ears, gastrointestinal tract, leptomeninges, and oral and genital mucous membranes. It can arise from normal skin or develop within existing moles. In its early stages, melanoma can present as melanoma in situ, which refers to abnormal melanocytes confined to the epidermis. Recognizing and diagnosing melanoma and its precursor at this stage are vital for timely intervention and improved patient outcomes.
MART-1 (Melan-A) protein and its role in Melanoma:
Melanoma-associated antigen recognized by T cell 1 (MART-1) is a specific protein expressed by normal melanocytes and with increased expression in most melanoma cells. MART-1 forms a complex with Pmel17 and affects its expression, stability, trafficking, and the processing which is required for melanosome structure and maturation thus, regulating mammalian pigmentation. MLANA/MART1 gene expression is restricted to melanocytes, melanomas, and retinal pigment epithelium. It has recently been found to localize to vesicles, including melanosomes, suggesting a role in melanosome biogenesis.
Subscribe to our newsletter
Don't miss out on the latest news, exclusive updates, and special offers.
Do you have questions? Contact Us